Osteopore, an Australian-Singaporean regenerative medicine company, initiated first-in-human trials in Singapore for its knee preservation treatment using HS3 and aXOpore.

The study, being conducted at Singapore's National University Hospital, aims to enrol 12 patients to verify treatment safety and efficacy in enhancing bone regeneration after knee surgery.

Osteopore aims to advance recovery times and patient outcomes with this innovative technology.